Global Melanoma Cancer Diagnostics Market Research Report 2023

Melanoma Cancer Diagnostics Market

Melanoma is a type of skin cancer developing from pigment-containing cells known as melanocytes. Melanoma cancer diagnostics is to diagnose melanoma with biopsy. During a biopsy, all or the part of mole or growth over the skin is removed to test and analyze the sample. Common biopsy procedures used to diagnose melanoma are punch biopsy, incisional biopsy, and excisional biopsy.

The global Melanoma Cancer Diagnostics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Melanoma Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Melanoma Cancer Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Melanoma Cancer Diagnostics in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Melanoma Cancer Diagnostics include AB Sciences, Incyte, Merck, Novartis, Pierre Fabre, Amgen, AstraZeneca, Bristol-Myers Squibb and Daiichi Sankyo, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Melanoma Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Melanoma Cancer Diagnostics.

The Melanoma Cancer Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Melanoma Cancer Diagnostics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Melanoma Cancer Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Scope of Melanoma Cancer Diagnostics Market Report

Core Chapters

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Melanoma Cancer Diagnostics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Fluorescent In Situ Hybridization (FISH) Tests

1.2.3 Comparative Genomic Hybridization (CGH) Tests

1.2.4 Immunohistochemical (IHC) Tests

1.3 Market by Application

1.3.1 Global Melanoma Cancer Diagnostics Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Cancer Research Centres

1.3.5 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Melanoma Cancer Diagnostics Market Perspective (2018-2029)

2.2 Melanoma Cancer Diagnostics Growth Trends by Region

2.2.1 Global Melanoma Cancer Diagnostics Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Melanoma Cancer Diagnostics Historic Market Size by Region (2018-2023)

2.2.3 Melanoma Cancer Diagnostics Forecasted Market Size by Region (2024-2029)

2.3 Melanoma Cancer Diagnostics Market Dynamics

2.3.1 Melanoma Cancer Diagnostics Industry Trends

2.3.2 Melanoma Cancer Diagnostics Market Drivers

2.3.3 Melanoma Cancer Diagnostics Market Challenges

2.3.4 Melanoma Cancer Diagnostics Market Restraints

3.1 Global Top Melanoma Cancer Diagnostics Players by Revenue

3.1.1 Global Top Melanoma Cancer Diagnostics Players by Revenue (2018-2023)

3.1.2 Global Melanoma Cancer Diagnostics Revenue Market Share by Players (2018-2023)

3.2 Global Melanoma Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Melanoma Cancer Diagnostics Revenue

3.4 Global Melanoma Cancer Diagnostics Market Concentration Ratio

3.4.1 Global Melanoma Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Melanoma Cancer Diagnostics Revenue in 2022

3.5 Melanoma Cancer Diagnostics Key Players Head office and Area Served

3.6 Key Players Melanoma Cancer Diagnostics Product Solution and Service

3.7 Date of Enter into Melanoma Cancer Diagnostics Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Melanoma Cancer Diagnostics Historic Market Size by Type (2018-2023)

4.2 Global Melanoma Cancer Diagnostics Forecasted Market Size by Type (2024-2029)

5.1 Global Melanoma Cancer Diagnostics Historic Market Size by Application (2018-2023)

5.2 Global Melanoma Cancer Diagnostics Forecasted Market Size by Application (2024-2029)

6.1 North America Melanoma Cancer Diagnostics Market Size (2018-2029)

6.2 North America Melanoma Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Melanoma Cancer Diagnostics Market Size by Country (2018-2023)

6.4 North America Melanoma Cancer Diagnostics Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Melanoma Cancer Diagnostics Market Size (2018-2029)

7.2 Europe Melanoma Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Melanoma Cancer Diagnostics Market Size by Country (2018-2023)

7.4 Europe Melanoma Cancer Diagnostics Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Melanoma Cancer Diagnostics Market Size (2018-2029)

8.2 Asia-Pacific Melanoma Cancer Diagnostics Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Melanoma Cancer Diagnostics Market Size by Region (2018-2023)

8.4 Asia-Pacific Melanoma Cancer Diagnostics Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Melanoma Cancer Diagnostics Market Size (2018-2029)

9.2 Latin America Melanoma Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Melanoma Cancer Diagnostics Market Size by Country (2018-2023)

9.4 Latin America Melanoma Cancer Diagnostics Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Melanoma Cancer Diagnostics Market Size (2018-2029)

10.2 Middle East & Africa Melanoma Cancer Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Melanoma Cancer Diagnostics Market Size by Country (2018-2023)

10.4 Middle East & Africa Melanoma Cancer Diagnostics Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 AB Sciences

11.1.1 AB Sciences Company Detail

11.1.2 AB Sciences Business Overview

11.1.3 AB Sciences Melanoma Cancer Diagnostics Introduction

11.1.4 AB Sciences Revenue in Melanoma Cancer Diagnostics Business (2018-2023)

11.1.5 AB Sciences Recent Development

11.2 Incyte

11.2.1 Incyte Company Detail

11.2.2 Incyte Business Overview

11.2.3 Incyte Melanoma Cancer Diagnostics Introduction

11.2.4 Incyte Revenue in Melanoma Cancer Diagnostics Business (2018-2023)

11.2.5 Incyte Recent Development

11.3 Merck

11.3.1 Merck Company Detail

11.3.2 Merck Business Overview

11.3.3 Merck Melanoma Cancer Diagnostics Introduction

11.3.4 Merck Revenue in Melanoma Cancer Diagnostics Business (2018-2023)

11.3.5 Merck Recent Development

11.4 Novartis

11.4.1 Novartis Company Detail

11.4.2 Novartis Business Overview

11.4.3 Novartis Melanoma Cancer Diagnostics Introduction

11.4.4 Novartis Revenue in Melanoma Cancer Diagnostics Business (2018-2023)

11.4.5 Novartis Recent Development

11.5 Pierre Fabre

11.5.1 Pierre Fabre Company Detail

11.5.2 Pierre Fabre Business Overview

11.5.3 Pierre Fabre Melanoma Cancer Diagnostics Introduction

11.5.4 Pierre Fabre Revenue in Melanoma Cancer Diagnostics Business (2018-2023)

11.5.5 Pierre Fabre Recent Development

11.6 Amgen

11.6.1 Amgen Company Detail

11.6.2 Amgen Business Overview

11.6.3 Amgen Melanoma Cancer Diagnostics Introduction

11.6.4 Amgen Revenue in Melanoma Cancer Diagnostics Business (2018-2023)

11.6.5 Amgen Recent Development

11.7 AstraZeneca

11.7.1 AstraZeneca Company Detail

11.7.2 AstraZeneca Business Overview

11.7.3 AstraZeneca Melanoma Cancer Diagnostics Introduction

11.7.4 AstraZeneca Revenue in Melanoma Cancer Diagnostics Business (2018-2023)

11.7.5 AstraZeneca Recent Development

11.8 Bristol-Myers Squibb

11.8.1 Bristol-Myers Squibb Company Detail

11.8.2 Bristol-Myers Squibb Business Overview

11.8.3 Bristol-Myers Squibb Melanoma Cancer Diagnostics Introduction

11.8.4 Bristol-Myers Squibb Revenue in Melanoma Cancer Diagnostics Business (2018-2023)

11.8.5 Bristol-Myers Squibb Recent Development

11.9 Daiichi Sankyo

11.9.1 Daiichi Sankyo Company Detail

11.9.2 Daiichi Sankyo Business Overview

11.9.3 Daiichi Sankyo Melanoma Cancer Diagnostics Introduction

11.9.4 Daiichi Sankyo Revenue in Melanoma Cancer Diagnostics Business (2018-2023)

11.9.5 Daiichi Sankyo Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Melanoma Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Fluorescent In Situ Hybridization (FISH) Tests

    Table 3. Key Players of Comparative Genomic Hybridization (CGH) Tests

    Table 4. Key Players of Immunohistochemical (IHC) Tests

    Table 5. Global Melanoma Cancer Diagnostics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 6. Global Melanoma Cancer Diagnostics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 7. Global Melanoma Cancer Diagnostics Market Size by Region (2018-2023) & (US$ Million)

    Table 8. Global Melanoma Cancer Diagnostics Market Share by Region (2018-2023)

    Table 9. Global Melanoma Cancer Diagnostics Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 10. Global Melanoma Cancer Diagnostics Market Share by Region (2024-2029)

    Table 11. Melanoma Cancer Diagnostics Market Trends

    Table 12. Melanoma Cancer Diagnostics Market Drivers

    Table 13. Melanoma Cancer Diagnostics Market Challenges

    Table 14. Melanoma Cancer Diagnostics Market Restraints

    Table 15. Global Melanoma Cancer Diagnostics Revenue by Players (2018-2023) & (US$ Million)

    Table 16. Global Melanoma Cancer Diagnostics Market Share by Players (2018-2023)

    Table 17. Global Top Melanoma Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Melanoma Cancer Diagnostics as of 2022)

    Table 18. Ranking of Global Top Melanoma Cancer Diagnostics Companies by Revenue (US$ Million) in 2022

    Table 19. Global 5 Largest Players Market Share by Melanoma Cancer Diagnostics Revenue (CR5 and HHI) & (2018-2023)

    Table 20. Key Players Headquarters and Area Served

    Table 21. Key Players Melanoma Cancer Diagnostics Product Solution and Service

    Table 22. Date of Enter into Melanoma Cancer Diagnostics Market

    Table 23. Mergers & Acquisitions, Expansion Plans

    Table 24. Global Melanoma Cancer Diagnostics Market Size by Type (2018-2023) & (US$ Million)

    Table 25. Global Melanoma Cancer Diagnostics Revenue Market Share by Type (2018-2023)

    Table 26. Global Melanoma Cancer Diagnostics Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 27. Global Melanoma Cancer Diagnostics Revenue Market Share by Type (2024-2029)

    Table 28. Global Melanoma Cancer Diagnostics Market Size by Application (2018-2023) & (US$ Million)

    Table 29. Global Melanoma Cancer Diagnostics Revenue Market Share by Application (2018-2023)

    Table 30. Global Melanoma Cancer Diagnostics Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 31. Global Melanoma Cancer Diagnostics Revenue Market Share by Application (2024-2029)

    Table 32. North America Melanoma Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 33. North America Melanoma Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)

    Table 34. North America Melanoma Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)

    Table 35. Europe Melanoma Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 36. Europe Melanoma Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)

    Table 37. Europe Melanoma Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)

    Table 38. Asia-Pacific Melanoma Cancer Diagnostics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 39. Asia-Pacific Melanoma Cancer Diagnostics Market Size by Region (2018-2023) & (US$ Million)

    Table 40. Asia-Pacific Melanoma Cancer Diagnostics Market Size by Region (2024-2029) & (US$ Million)

    Table 41. Latin America Melanoma Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 42. Latin America Melanoma Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)

    Table 43. Latin America Melanoma Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)

    Table 44. Middle East & Africa Melanoma Cancer Diagnostics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 45. Middle East & Africa Melanoma Cancer Diagnostics Market Size by Country (2018-2023) & (US$ Million)

    Table 46. Middle East & Africa Melanoma Cancer Diagnostics Market Size by Country (2024-2029) & (US$ Million)

    Table 47. AB Sciences Company Detail

    Table 48. AB Sciences Business Overview

    Table 49. AB Sciences Melanoma Cancer Diagnostics Product

    Table 50. AB Sciences Revenue in Melanoma Cancer Diagnostics Business (2018-2023) & (US$ Million)

    Table 51. AB Sciences Recent Development

    Table 52. Incyte Company Detail

    Table 53. Incyte Business Overview

    Table 54. Incyte Melanoma Cancer Diagnostics Product

    Table 55. Incyte Revenue in Melanoma Cancer Diagnostics Business (2018-2023) & (US$ Million)

    Table 56. Incyte Recent Development

    Table 57. Merck Company Detail

    Table 58. Merck Business Overview

    Table 59. Merck Melanoma Cancer Diagnostics Product

    Table 60. Merck Revenue in Melanoma Cancer Diagnostics Business (2018-2023) & (US$ Million)

    Table 61. Merck Recent Development

    Table 62. Novartis Company Detail

    Table 63. Novartis Business Overview

    Table 64. Novartis Melanoma Cancer Diagnostics Product

    Table 65. Novartis Revenue in Melanoma Cancer Diagnostics Business (2018-2023) & (US$ Million)

    Table 66. Novartis Recent Development

    Table 67. Pierre Fabre Company Detail

    Table 68. Pierre Fabre Business Overview

    Table 69. Pierre Fabre Melanoma Cancer Diagnostics Product

    Table 70. Pierre Fabre Revenue in Melanoma Cancer Diagnostics Business (2018-2023) & (US$ Million)

    Table 71. Pierre Fabre Recent Development

    Table 72. Amgen Company Detail

    Table 73. Amgen Business Overview

    Table 74. Amgen Melanoma Cancer Diagnostics Product

    Table 75. Amgen Revenue in Melanoma Cancer Diagnostics Business (2018-2023) & (US$ Million)

    Table 76. Amgen Recent Development

    Table 77. AstraZeneca Company Detail

    Table 78. AstraZeneca Business Overview

    Table 79. AstraZeneca Melanoma Cancer Diagnostics Product

    Table 80. AstraZeneca Revenue in Melanoma Cancer Diagnostics Business (2018-2023) & (US$ Million)

    Table 81. AstraZeneca Recent Development

    Table 82. Bristol-Myers Squibb Company Detail

    Table 83. Bristol-Myers Squibb Business Overview

    Table 84. Bristol-Myers Squibb Melanoma Cancer Diagnostics Product

    Table 85. Bristol-Myers Squibb Revenue in Melanoma Cancer Diagnostics Business (2018-2023) & (US$ Million)

    Table 86. Bristol-Myers Squibb Recent Development

    Table 87. Daiichi Sankyo Company Detail

    Table 88. Daiichi Sankyo Business Overview

    Table 89. Daiichi Sankyo Melanoma Cancer Diagnostics Product

    Table 90. Daiichi Sankyo Revenue in Melanoma Cancer Diagnostics Business (2018-2023) & (US$ Million)

    Table 91. Daiichi Sankyo Recent Development

    Table 92. Research Programs/Design for This Report

    Table 93. Key Data Information from Secondary Sources

    Table 94. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Melanoma Cancer Diagnostics Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Melanoma Cancer Diagnostics Market Share by Type: 2022 VS 2029

    Figure 3. Fluorescent In Situ Hybridization (FISH) Tests Features

    Figure 4. Comparative Genomic Hybridization (CGH) Tests Features

    Figure 5. Immunohistochemical (IHC) Tests Features

    Figure 6. Global Melanoma Cancer Diagnostics Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 7. Global Melanoma Cancer Diagnostics Market Share by Application: 2022 VS 2029

    Figure 8. Hospitals Case Studies

    Figure 9. Clinics Case Studies

    Figure 10. Cancer Research Centres Case Studies

    Figure 11. Others Case Studies

    Figure 12. Melanoma Cancer Diagnostics Report Years Considered

    Figure 13. Global Melanoma Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 14. Global Melanoma Cancer Diagnostics Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 15. Global Melanoma Cancer Diagnostics Market Share by Region: 2022 VS 2029

    Figure 16. Global Melanoma Cancer Diagnostics Market Share by Players in 2022

    Figure 17. Global Top Melanoma Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Melanoma Cancer Diagnostics as of 2022)

    Figure 18. The Top 10 and 5 Players Market Share by Melanoma Cancer Diagnostics Revenue in 2022

    Figure 19. North America Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 20. North America Melanoma Cancer Diagnostics Market Share by Country (2018-2029)

    Figure 21. United States Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Canada Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. Europe Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. Europe Melanoma Cancer Diagnostics Market Share by Country (2018-2029)

    Figure 25. Germany Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. France Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. U.K. Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Italy Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Russia Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Nordic Countries Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Asia-Pacific Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Asia-Pacific Melanoma Cancer Diagnostics Market Share by Region (2018-2029)

    Figure 33. China Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. Japan Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. South Korea Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Southeast Asia Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. India Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Australia Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Latin America Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Latin America Melanoma Cancer Diagnostics Market Share by Country (2018-2029)

    Figure 41. Mexico Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Brazil Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Middle East & Africa Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Middle East & Africa Melanoma Cancer Diagnostics Market Share by Country (2018-2029)

    Figure 45. Turkey Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Saudi Arabia Melanoma Cancer Diagnostics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 47. AB Sciences Revenue Growth Rate in Melanoma Cancer Diagnostics Business (2018-2023)

    Figure 48. Incyte Revenue Growth Rate in Melanoma Cancer Diagnostics Business (2018-2023)

    Figure 49. Merck Revenue Growth Rate in Melanoma Cancer Diagnostics Business (2018-2023)

    Figure 50. Novartis Revenue Growth Rate in Melanoma Cancer Diagnostics Business (2018-2023)

    Figure 51. Pierre Fabre Revenue Growth Rate in Melanoma Cancer Diagnostics Business (2018-2023)

    Figure 52. Amgen Revenue Growth Rate in Melanoma Cancer Diagnostics Business (2018-2023)

    Figure 53. AstraZeneca Revenue Growth Rate in Melanoma Cancer Diagnostics Business (2018-2023)

    Figure 54. Bristol-Myers Squibb Revenue Growth Rate in Melanoma Cancer Diagnostics Business (2018-2023)

    Figure 55. Daiichi Sankyo Revenue Growth Rate in Melanoma Cancer Diagnostics Business (2018-2023)

    Figure 56. Bottom-up and Top-down Approaches for This Report

    Figure 57. Data Triangulation

    Figure 58. Key Executives Interviewed